An interesting "what if"There are long time shareholders who have picked up on the latest CC that centers around the belief that "Since RVX had only 25MM to work with, could only hold a 6 month trial and could only afford 300 plus patients they missed the .6 endpoint." "If they would have had the extra 50MM, had run the trial for two years and had double the enrollment they could have achieved the needed .6"
How valid is this thinking? What if BP embraces this thought, buys the IP and runs a new trial. Is this a viable strategy? I don't live in this space so I have no idea but I'd be interested if anyone else shares this belief and if this might be a factor during the Sept 2 discussions. "What If?"